CRISPR Treatment Lowers 'Bad' Cholesterol in Half for a Year

Topic: Health

A new CRISPR treatment called CTX310 was tested on 15 people with high cholesterol. The results showed that it lowered 'bad' cholesterol by 52.5% and triglycerides by 47.8% after one year. This is a promising breakthrough in treating cardiovascular disease.

A team of researchers from Cleveland Clinic conducted a Phase 1 clinical trial to test the safety and effectiveness of CTX310, a CRISPR-Cas9 gene-editing therapy.

The treatment works by targeting a specific gene called ANGPTL3, which helps regulate fats in the blood. When this gene is disabled, it reduces the levels of 'bad' cholesterol and triglycerides in the blood. The researchers tested CTX310 on 15 people with high cholesterol who had not responded well to medications.

The participants received a single infusion of CTX310 at doses ranging from 0.1 to 0.8 mg/kg, along with corticosteroids and antihistamines to prevent any adverse reactions. The researchers then monitored the patients for one year to see if the cholesterol and triglyceride levels remained low.

The results showed that after 12 months, the participants who received the highest dose had a 52.5% reduction in 'bad' cholesterol and a 47.8% drop in triglycerides compared to their baseline levels. This is a significant breakthrough in treating cardiovascular disease, which is one of the leading causes of death worldwide.

The study was funded by CRISPR Therapeutics AG, and Dr. Luke Laffin, the lead researcher, has received research funding from the same company.

Why It Matters

This breakthrough could potentially save millions of lives in India, where cardiovascular disease is a major health concern. If this treatment becomes widely available, it could be a game-changer for people with high cholesterol and triglyceride levels.

Key Facts

• 15 people participated in the clinical trial to test CTX310.
• The treatment lowered 'bad' cholesterol by 52.5% and triglycerides by 47.8% after one year.
• CTX310 targets a specific gene called ANGPTL3, which helps regulate fats in the blood.
• The study was funded by CRISPR Therapeutics AG.
• Dr. Luke Laffin has received research funding from CRISPR Therapeutics AG.

Key Terms

CRISPR-Cas9

A gene-editing technology that allows scientists to make targeted changes to specific parts of a person's DNA.

ANGPTL3

A gene that helps regulate fats in the blood.

Implications

This breakthrough could potentially save millions of lives in India, where cardiovascular disease is a major health concern. If this treatment becomes widely available, it could be a game-changer for people with high cholesterol and triglyceride levels.